Ironwood Pharmaceuticals Inc Cash Flow Conversion Efficiency
Ironwood Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) has a cash flow conversion efficiency ratio of -0.360x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($58.28 Million) by net assets ($-161.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ironwood Pharmaceuticals Inc (2007–2025)
Cash flow conversion efficiency of Ironwood Pharmaceuticals Inc from 2007 to 2025. This chart illustrates how Ironwood Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IRWD live share price for real-time trading data and today's change.
Ironwood Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Ironwood Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ironwood Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ironwood Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see IRWD stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cuckoo Electronics Co Ltd
KO:192400
|
0.022x |
|
Musti Group Oyj
HE:MUSTI
|
0.079x |
|
Dongguan Golden Sun Abrasives Co Ltd
SHE:300606
|
0.038x |
|
Amos Luzon Development and Energy Group Ltd
TA:LUZN
|
-0.013x |
|
Australian Agricultural Company Ltd
AU:AAC
|
0.001x |
|
Hg Technologies Co Ltd
SHE:300847
|
0.031x |
|
Ichitan Group Public Company Limited
BK:ICHI
|
-0.015x |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
N/A |
Annual Cash Flow Conversion Efficiency for Ironwood Pharmaceuticals Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Ironwood Pharmaceuticals Inc from 2007 to 2025. Review Ironwood Pharmaceuticals Inc (IRWD) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-261.83 Million | $127.04 Million | -0.485x | -41.20% |
| 2024-12-31 | $-301.33 Million | $103.55 Million | -0.344x | +35.12% |
| 2023-12-31 | $-346.30 Million | $183.43 Million | -0.530x | -226.22% |
| 2022-12-31 | $652.38 Million | $273.76 Million | 0.420x | -2.91% |
| 2021-12-31 | $605.91 Million | $261.89 Million | 0.432x | -83.96% |
| 2020-12-31 | $62.64 Million | $168.84 Million | 2.695x | +2443.52% |
| 2019-12-31 | $-93.25 Million | $10.72 Million | -0.115x | -131.86% |
| 2018-12-31 | $-196.37 Million | $-70.88 Million | 0.361x | +103.57% |
| 2017-12-31 | $9.85 Million | $-99.56 Million | -10.110x | -2552.05% |
| 2016-12-31 | $66.72 Million | $-25.43 Million | -0.381x | +66.09% |
| 2015-12-31 | $95.12 Million | $-106.93 Million | -1.124x | +36.02% |
| 2014-12-31 | $88.55 Million | $-155.57 Million | -1.757x | +75.43% |
| 2013-12-31 | $38.23 Million | $-273.36 Million | -7.151x | -1379.39% |
| 2012-12-31 | $144.05 Million | $-69.63 Million | -0.483x | +29.42% |
| 2011-12-31 | $109.86 Million | $-75.24 Million | -0.685x | -60.93% |
| 2010-12-31 | $159.55 Million | $-67.90 Million | -0.426x | -3275.65% |
| 2009-12-31 | $-298.34 Million | $-4.00 Million | 0.013x | -89.05% |
| 2008-12-31 | $-230.41 Million | $-28.20 Million | 0.122x | +222.94% |
| 2007-12-31 | $-178.37 Million | $-6.76 Million | 0.038x | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more